Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Kairos Pharma, LTD. (KAPA)

Kairos Pharma named winner of 2026 Biotech Breakthrough Award for ENV-105 cancer program

Neutral Impact 1 of 5 product/contract Written later

Kairos Pharma announced it was named a winner of the 2026 Biotech Breakthrough Awards in the Cancer Immunology Solution of the Year category for its ENV-105 (carotuximab) work in metastatic prostate cancer and non-small cell lung cancer. The filing reports no financial results, guidance, or transaction, so the award itself does not change reported financial figures.

Key points

  • Award: Cancer Immunology Solution of the Year, 2026 Biotech Breakthrough Awards
  • Lead candidate ENV-105 (carotuximab) is in development for metastatic prostate cancer and non-small cell lung cancer
  • Press release references earlier positive interim Phase 2 efficacy data for ENV-105 with apalutamide in metastatic castration-resistant prostate cancer
  • Press release dated November 5, 2026, furnished as Exhibit 99.1

The filing

CompanyKairos Pharma, LTD. (KAPA)
Form8-K, current report
Filed with the SECNov 5, 2026, 9:15 AM ET
Accession number0001493152-26-050094

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.